NIH-funded study shines light on disease mechanisms, pointing to possible therapeutic targets
Press Releases
Image
Image
Wednesday, January 31, 2024
Proteins could serve as biomarkers that improve diagnosis and guide the development of novel therapies
Image
Monday, May 8, 2023
Scientists at the National Institutes of Health have identified new genetic risk factors for two types of non-Alzheimer’s dementia.
Image
Monday, February 28, 2022
Researchers from two independent research teams have discovered how the mislocalization of a protein, known as TDP-43, alters the genetic instructions for UNC13A, providing a possible therapeutic target that could also have implications in treating amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other forms of dementia.
Image
Thursday, December 3, 2020
A study led by researchers at the National Institutes of Health has made a surprising connection between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), two disorders of the nervous system, and the genetic mutation normally understood to cause Huntington’s disease.
Image
Wednesday, June 17, 2020
The National Institutes of Health plans to invest $25 million over 5 years in a new program to spur innovative research on amyotrophic lateral sclerosis (ALS), a progressive and fatal neurological disease that weakens and eventually paralyzes voluntary muscles.
Image
Monday, March 2, 2020
Researchers report an advance in the development of a blood test that could help detect pathological Alzheimer’s disease in people who are showing signs of dementia.
Image
Image
Image
